Research on advanced gastric cancer with small molecular targeted drugs in China | | gastric cancer drugs _ a breakthrough news

Xinhuanet, Beijing, December 13 (reporter Hu Hao)-according to China's State Health Commission website, 13th, independently developed in China for the treatment of advanced gastric cancer with small molecular targeted drugs, "APA for dasatinib mesylate tablets" won the State food and Drug Administration approved for marketing, this is China's major national new drug created major science and technology projects, supported by another major breakthrough in the field of cancer therapy.

Health Planning Commission's Web site noted that the APA for dasatinib is the world's first advanced gastric cancer was proved safe and effective in anti-angiogenesis-targeted small molecule drugs, after the failure of standard chemotherapy for advanced gastric cancer, significantly prolonged survival time alone. Meanwhile, the drug is stomach cancer targeted drugs only in an oral formulation, can improve the patients ' treatment compliance, and significantly reduce the cost of treatment.

According to one of the lead researchers in the drug, Li Jin in cancer hospital affiliated to Fudan University Professor, are powers of gastric cancer in China, statistics show, about 950,000 new cases of gastric cancer in the world last year, China accounted for 47%. Its incidence in malignant tumors in China ranked 2nd, mortality was ranked 3rd. Because the early symptoms are not typical and routine gastroscopy examination not yet universal, about 60% to 80% patients had nearly late, limited treatment available, poor prognosis, the 5-year survival rate of less than 20%. In recent decades, while devoting a lot of effort, but the standard treatment for advanced gastric cancer after the failure of new drug research and development has not been a breakthrough, leading to this population do not have access to effective treatment.

After nearly ten years of research by Professor Li Jin and Qin Shu-Kui PLA Nanjing Army Day Hospital Professor, led 38 medical centers to participate in research and development of APA for dasatinib is "Eleven-Five" and "Twelve-Five" one of the major new drugs created special.

It is understood that the major new drugs created since the implementation of major science and technology launched in 2008, has accumulated new drug certificate obtained 83, clinical official written reply 118 pieces, completing more than more than more than 200 varieties of drug technology to effectively promote the bio-pharmaceutical industry rapid development.

Xinhua NET